【摘要】 目的 评估血浆CD100浓度与鼻咽癌复发或转移及其预后相关性,并探讨其作为预测鼻咽癌预后标志物的可行性。方法 酶联免疫吸附试验(Elisa)测定60例入院时未经治疗的鼻咽癌患者和23例健康受试者血浆CD100浓度,荧光定量PCR检测血浆EBV-DNA载量。统计分析鼻咽癌患者血浆CD100浓度与预后的关系。结果 鼻咽癌患者血浆CD100浓度高于健康对照组(P<0.0001),并且复发转移组血浆CD100浓度明显高于无复发转移组(P<0.0001);生存分析显示血浆CD100与鼻咽癌5年无进展生存期(PFS)相关(P<0.0001),是鼻咽癌PFS的独立预后因素。结论 血浆CD100与鼻咽癌复发、转移密切相关,可作预测预后标志物。更多还原

【Abstract】 Objective To evaluate whether the plasma CD100(pCD100) concentration could predict the clinical outcome of patients with nasopharyngeal carcinoma(NPC).Methods A total of 60 patients and 23 healthy doners were enrolled.Their plasma concentrations of CD 100 were measured by ELISA,and EBV DNA loads were detected by real-time PCR.The relationship between pCD100 concentrations and outcomes of NPC patients was analyzed.Results The pCD100 concentrations were higher in NPC patients than in health controls(P <0.0001).In addition,the pCD100 concentrations were significantly elevated in NPC patients with recurrence or metastasis than those without recurrent and metastasis(P<0.0001).Cox analysis showed that the concentration of pCD100 was associated with 5-year progression-free survival(PFS) rate in NPC patients(P <0.0001),and was an independent prognostic factor for PFS of NPC patients.Conclusion The pCD100 concentration is associated with NPC recurrence or metastasis and could be a potential noninvasive prognostic marker for NPC.更多还原